1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A

SSZSE:002693
9.07
CNY
+0.09
(+1.00%)
0.04EPS
146.62P/E
3.92BMarket Cap
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Class A
SZSE:002693
(Shenzhen Stock Exchange)

Recent

price

9.07

P/E

ratio

146.62

div

yld

0.19%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.37
0.44
0.36
0.37
0.4
0.57
0.36
0.78
0.83
0.84
0.66
0.79
0.61
0.56
0.42
0.73
0.66
Revenue per Share
0.21
0.23
0.19
0.17
0.15
0.13
-0.96
0.02
-0.17
0.06
-0.13
-0.05
0.02
-0.12
-0.19
0.05
0.06
Basic EPS, GAAP
0.15
-0.13
0.06
-0.02
-0.16
-0.6
-0.36
-0.29
0.06
0.04
-0.15
-0.02
-0.02
-0.09
-0.16
0.05
- -
Free Cash Flow per Basic Share
- -
0.25
- -
0.11
0.09
0.11
0.06
0.02
0.04
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Dividend per Share
0.52
0.75
2.09
2.15
2.21
2.21
1.37
1.46
1.29
1.35
1.22
1.17
1.24
1.13
0.95
0.99
1.03
Book Value per Share
0.47
0.69
2.01
2.07
2.09
1.89
1.1
1.21
1.05
1.06
0.89
0.79
0.84
0.72
0.53
0.54
0.56
Tangible Book Value per Share
305
305
364
401
405
405
405
316
409
411
410
407
451
423
412
381
415
Basic Weighted Avg Shares
113
134
130
150
161
231
145
247
337
347
269
320
275
236
174
277
272
Sales/Revenue/Turnover
61.54
57.05
50.9
36.68
33.05
24.02
-71.69
-11.19
-19.99
-6.1
-20.56
-13.66
-10.67
-9.47
-39.13
8.69
12.39
Operating Margin (%)
5
6
8
13
17
21
29
43
56
59
57
54
58
53
53
53
- -
Depreciation Expense
64
70
68
67
61
53
-388
6
-69
25
-53
-20
9
-51
-78
19
27
Net Income, GAAP
10.99
12
14.95
15.08
14.77
15.42
- -
56.86
- -
14.15
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
56.9
52.74
52.44
44.63
37.71
22.81
-267.62
2.56
-20.6
7.11
-19.79
-6.35
3.28
-21.51
-44.95
6.88
9.82
Profit Margin (%)
89
78
642
634
598
-41
-104
357
265
132
68
57
-67
-5
-21
-102
-119
Working Capital
- -
- -
- -
- -
- -
145
297
367
306
167
167
167
- -
135
185
89
58
LT Debt
158
228
846
871
896
928
553
762
670
678
598
567
581
518
412
421
429
Total Equity
52.02
34.77
11.5
7.37
6.87
4.16
- -
0.03
- -
0.74
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
54.49
36.48
11.67
7
6.44
5.73
- -
1.7
- -
5.35
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
54.49
36.48
12.66
7.78
6.88
5.78
-52.46
1.1
-12.48
4.62
-10.26
-4.17
1.81
-10.3
-18.11
4.73
6.61
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
125
140
142
LT Borrowings
89
82
58
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
415
415
415
Market Capitalization
2,886
3,305
3,923

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
205
200
194
Cash, Cash Equivalents & STI
59
74
40
Accounts Receivable, Net
62
38
48
Inventories
66
71
85
Total Current Liabilities
307
303
313
Payables & Accruals
- -
- -
- -
ST Debt
125
140
142
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.72%
-6.4%
2.17%
Free Cash Flow
-51.2%
48.17%
-126.89%
Net Income, GAAP
-352.99%
-187.85%
-124.32%
Sales/Revenue/Turnover
7.33%
4.65%
58.87%
Total Cash Common Dividend
-5.45%
-4.5%
1.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
43
52
32
47
174
2025
37
47
- -
108
277
2026
48
69
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.05
-0.1
-0.19
2025
-0.02
-0.02
- -
0.05
0.05
2026
0.01
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) manufactures and markets chemically synthesized peptide drugs, active pharmaceutical ingredients (APIs), and finished dosage forms principally in China with global export capabilities. The company offers peptide injections including thymalfasin, thymopentin, bivalirudin, eptifibatide, liraglutide, exenatide, and somatostatin; lyophilized products such as bortezomib and pantoprazole for injection; oncology injectables including paclitaxel; oral solid dosage forms; and other sterile injectables like levocarnitine, clindamycin hydrochloride, famotidine, ligustrazine phosphate, vitamin B6, and sodium ferulate, alongside contract development and manufacturing organization (CDMO) services for APIs, lyophilized products, cartridges, and oncology formulations. Founded in 2000 and headquartered at No. 16 Xingguo Road, Xiuying District, Haikou, Hainan Province, China, it operates FDA- and EU-approved facilities including its Haikou headquarters and Ningbo Shuangcheng Pharmaceuticals Ltd., a holding subsidiary established in 2015 focused on oncology injectables and oral solids. Recent developments include a December 2024 revision to its pharmaceutical production license expanding API production (C139, C141) at the Haikou facility for registered declarations; a supplementary agreement with Emerge Bioscience Pte. Ltd. on a license and supply deal; receipt of a remaining USD 3 million milestone payment from HKF; and plans announced in 2025 for a restricted stock and stock option incentive scheme, alongside a canceled major asset restructuring involving the prospective acquisition of Ningbo Aura Semiconductor Co., Ltd. shares through issuance and cash.